Back to search results

alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells

Abroad (travel likely)RecruitingPHASE1

Conditions

Unresectable Metastatic Colorectal Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Moffit Cancer Center, Tampa, Florida, United States

    Contact: Study coordinator (Kim Dae Won, MD)
    Contact: Principal Investigator (Kim Dae Won)

  • Institut Jules Bordet, Brussels, Belgium

    Contact: Study coordinator (Michel Dubuisson)
    Contact: Principal Investigator (Alain Hendlisz, MD)

  • UZ Antwerpen, Edegem, Belgium

    Contact: Study coordinator (Hans Prenen, MD)
    Contact: Principal Investigator (Hans Prenen, MD)

  • UZ Leuven, Leuven, Belgium

    Contact: Study coordinator (Hilde Marsé)
    Contact: Principal Investigator (Eric Van Cutsem, MD)
View source on ClinicalTrials.gov(opens in a new tab)